KOSDAQBiotech & Pharma086450

DongKookPharmaceuticalCo

₩24,400▼ 1.61%2026-11-18 close
Market Cap
₩1.1T
Turnover
₩7.8B
Volume
320K
Shares out.
45.2M
PER
15.4×
PBR
1.5×
EPS
₩1,551
Dividend Yield
0.84%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue nears KRW 1 trillion as profit growth slows

Third-quarter 2026 revenue rose 14.0% year on year to KRW 258.7 billion, but operating profit fell 4.1% to KRW 23.8 billion and has declined for two straight quarters since the first quarter of 2026.

  1. 1

    Annual revenue rose from KRW 661.6 billion in 2022 to KRW 926.9 billion in 2025, and operating profit grew for two consecutive years after the 2023 low of KRW 66.9 billion.

  2. 2

    Overseas sales for the nine months through September 2026 reached KRW 117 billion, about 2.4 times the KRW 49.3 billion of a year earlier, according to press reports of the quarterly report filed on November 16, 2026.

  3. 3

    Third-quarter profit attributable to owners of the parent fell 33.0% year on year to KRW 13.4 billion, with higher financing costs and an 18.5% rise in selling and administrative expenses cited as pressure points.

  4. 4

    Annual revenue would reach KRW 1 trillion if about KRW 231.4 billion more is booked in the fourth quarter on top of KRW 768.6 billion through September; the company did not state an annual revenue forecast in its quarterly report.

  5. 5

    Overseas expansion in health and beauty is driving top-line growth, while weakness at subsidiary DongKook Life Science kept consolidated growth below the parent-only level.

02

Business structure

Dong Kook Pharmaceutical operates in three segments: over-the-counter (OTC) drugs, prescription drugs (ETC), and health and beauty.

The OTC business centers on long-established brands such as the wound-care product Madecassol and the periodontal product Inadol, and Madecassol held a 35.9% domestic share of the wound-care market in 2024, according to reports citing company data.

The ETC business, which includes oncology and anesthesia products, generated KRW 115.2 billion in the first half of 2026 for a 22.6% revenue share. The health and beauty unit posted KRW 202.9 billion in the first half of 2026, up 39.8% year on year and about 2.2 times OTC sales of KRW 90.8 billion.

Securities analysts estimate that roughly 75 to 80 percent of healthcare revenue comes from cosmetics, led by the dermo-cosmetic brand Centellian24, whose flagship Madecassol cream passed 100 million cumulative units sold by September 2026.

Overseas sales reached KRW 117 billion through September 2026, or 15.2% of total revenue, up from 7.2% a year earlier. Parent-only exports were KRW 110.7 billion through September 2026, already above the KRW 76 billion recorded for all of 2025.

Subsidiary DongKook Life Science saw medical device sales decline amid a weaker diagnostic equipment market, and a contrast agent plant relocation weighed on consolidated growth. Parent-only R&D spending through September 2026 was KRW 26.2 billion, or 4.0% of parent-only revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩226.8B₩24.8B10.9%
2025Q4₩242.9B₩24.3B10.0%
2026Q1₩251B₩27.3B10.9%
2026Q2₩258.9B₩26.1B10.1%
2026Q3₩258.7B₩23.8B9.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩661.6B₩72.7B₩52.9B11.0%10.5%44.7%
2023₩731B₩66.9B₩47.2B9.1%8.7%45.7%
2024₩812.2B₩80.4B₩61.2B9.9%10.1%40.4%
2025₩926.9B₩96.6B₩66B10.4%9.9%39.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual revenue rose from KRW 661.6 billion in 2022 to KRW 731 billion in 2023 (up 10.5%), KRW 812.2 billion in 2024 (up 11.1%) and KRW 926.9 billion in 2025 (up 14.1%), growing for three consecutive years from 2023 with 2025 as the largest year in the 2022 to 2025 span.

Operating profit fell from KRW 72.7 billion in 2022 to KRW 66.9 billion in 2023 (down 8.0%), then rose to KRW 80.4 billion in 2024 (up 20.3%) and KRW 96.6 billion in 2025 (up 20.1%), increasing for two consecutive years.

The operating margin moved from 11.0% in 2022 to 9.1% in 2023, 9.9% in 2024 and 10.4% in 2025, a recovery since the 2023 low. Profit attributable to owners of the parent was KRW 52.9 billion in 2022, KRW 47.2 billion in 2023 (down 10.8%), KRW 61.2 billion in 2024 (up 29.8%) and KRW 66 billion in 2025 (up 7.8%).

Net profit including non-controlling interests, which differs from the owner-attributable figure, was KRW 73.9 billion in 2025.

At the end of 2025, total equity stood at KRW 763.7 billion, of which KRW 663.7 billion belonged to owners of the parent, and total liabilities were KRW 299.2 billion, with the debt ratio easing from 44.7% in 2022 to 39.2%.

Operating cash flow was KRW 40.9 billion in 2022, KRW 76.1 billion in 2024 and KRW 68.8 billion in 2025.

On a quarterly basis, revenue moved from KRW 226.8 billion in the third quarter of 2025 to KRW 242.9 billion in the fourth quarter (up 7.1% quarter on quarter), then KRW 251 billion, KRW 258.9 billion and KRW 258.7 billion in the first three quarters of 2026, with the third quarter up 14.0% year on year.

Operating profit peaked at KRW 27.3 billion in the first quarter of 2026 and then fell to KRW 26.1 billion and KRW 23.8 billion, the third quarter down 4.1% year on year and the second consecutive quarterly decline.

Third-quarter selling and administrative expenses rose 18.5% to KRW 117.6 billion, outpacing revenue growth, while financing costs climbed from about KRW 532 million to KRW 9.24 billion and weighed on owner-attributable profit.

The gap between consolidated and parent-only growth came from the subsidiary DongKook Life Science, with January to September parent-only operating profit up 23.3% against 6.9% on a consolidated basis.

05

Industry analysis

In domestic OTC wound care, Madecassol's share rose from 29.5% in 2022 to 31.7% in 2023 and 35.9% in 2024, according to reports citing company data. Inadol also holds a high share in periodontal treatment, so long-established OTC brands provide a stable base for the company.

OTC sales grew 4.6% in the first half of 2026, a single-digit pace. By contrast, the cosmetics business driving top-line growth operates in a market where competition is intensifying, and reports point to rising competition and marketing cost burdens as medium-term variables.

Overseas, cosmetics exports have overtaken the sales of the global business unit that handles drug exports. LS Securities estimated first-half 2026 cosmetics exports at KRW 53 billion to KRW 54 billion, against KRW 23.3 billion of global business unit sales over the same period.

In functional foods, sales through the Daiso channel rose more than 330% year on year after the listing began, and in February 2026 the company launched a nine-product lineup aimed at the low-priced segment.

In prescription drugs, a licensing and supply agreement with Spain's FAES FARMA is being used to pursue country-by-country approvals and launches in Latin America.

06

Outlook

The company did not give an annual revenue forecast in its quarterly report, so reaching KRW 1 trillion for 2026 is not yet a confirmed outcome. Still, KRW 768.6 billion through September plus about KRW 231.4 billion in the fourth quarter would reach that level.

The company said its global business unit posted results above plan on a three-quarter cumulative basis. Through the third quarter it had launched more than 20 new OTC products, including the pigmentation cream Melatension and the protective device product Madecamd MD cream.

In Latin America, licensing and supply agreements with FAES FARMA and a regional partner are being used to pursue country-by-country approvals and launches. The company presented the commercialization of new products, using its proprietary platform technology and open innovation, as a growth strategy.

Officials said the healthcare business unit's revenue rose 30.9% year on year in the third quarter of 2026, with cosmetics growing 40%. They also described plans to widen distribution and brand reach in North America, Europe, Japan and Southeast Asia.

An extraordinary shareholders' meeting on November 27, 2026 will consider a proposed change of corporate name. The next checkpoints are whether overseas growth continues alongside higher marketing costs and whether the operating margin recovers to the 10.4% level of 2025.

07

Valuation

PER
15.4×
PBR
1.5×
ROE
10.3%
EPS
₩1,551
BPS
₩15,731
Dividend per share
₩200

Valuation can be read by comparing the current share price with earnings and net asset value. The price-to-book ratio sits above 1x, which means the shares trade at a premium to net assets attributable to owners of the parent.

Owner-attributable profit for the latest four quarters through the third quarter of 2026 totals KRW 69.7 billion, slightly above the KRW 66 billion recorded for 2025.

Because profit has declined for two straight quarters since its first-quarter 2026 peak, the earnings trajectory is the main variable in how the multiples are read. A 33.0% year-on-year drop in third-quarter owner-attributable profit means the next quarter's earnings recovery will shape that interpretation.

Biopharma companies differ in multiples depending on business mix, so OTC and prescription-focused companies and those with large cosmetics exposure are not directly comparable on the same basis. A factual comparison must weigh business mix and earnings trend together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Rapid growth in overseas health and beauty sales

Overseas sales for the first nine months of 2026 reached KRW 117 billion, about 2.4 times the prior-year level of KRW 49.3 billion. Third-quarter overseas sales of KRW 43.8 billion were roughly 3.75 times the year-earlier quarter. The overseas share rose to 15.2%, changing a revenue mix that was previously concentrated in Korea.

Top-line growth and a path to KRW 1 trillion

Revenue for the first three quarters reached KRW 768.6 billion, up 12.4% year on year. Adding about KRW 231.4 billion in the fourth quarter would take annual revenue past KRW 1 trillion. Revenue grew 14.1% in 2025 to KRW 926.9 billion, extending a three-year run of increases.

Steady contribution from prescription drugs and new OTC products

Cumulative prescription drug sales through the third quarter rose 8.4% year on year. The OTC unit launched more than 20 new products through the third quarter. Health and beauty sales rose 39.8% in the first half of 2026, showing the effect of product line expansion.

09

Bear factors

Third-quarter profit decline and consecutive slowdown

Third-quarter operating profit was KRW 23.8 billion, down 4.1% year on year. Profit attributable to owners of the parent fell 33.0% to KRW 13.4 billion. Operating profit has declined for two consecutive quarters since peaking in the first quarter of 2026, so revenue growth has not carried through to profit.

Burden from selling costs and financing expenses

Third-quarter selling and administrative expenses rose 18.5% to KRW 117.6 billion, faster than the 14.0% revenue growth. Financing costs climbed from about KRW 532 million to KRW 9.24 billion. Marketing costs tied to overseas expansion and the shift in the cost structure are cited as obstacles to a profit recovery.

Subsidiary weakness and intensifying cosmetics competition

Subsidiary DongKook Life Science saw medical device sales fall as the diagnostic equipment market weakened, and incurred costs from relocating a contrast agent plant. Competition in cosmetics is intensifying, so sustaining Centellian24's growth is a challenge. Both factors kept consolidated growth below the parent-only level.

10

Risk factors

Cosmetics competition and marketing costs

Analysts estimate that about 75 to 80 percent of healthcare revenue comes from cosmetics, so business concentration is high. Growing competition could raise the marketing costs of expanding overseas distribution. Whether selling expense growth continues to exceed revenue growth is a point to monitor.

Earnings volatility at subsidiary DongKook Life Science

Subsidiary DongKook Life Science is undergoing restructuring, including lower medical device sales and a plant relocation. Consolidated results diverge from parent-only results depending on this subsidiary's performance. The timing of when portfolio changes will show up in earnings remains uncertain.

Financing costs and profit volatility

Third-quarter financing costs rose sharply and were reported as a factor behind the decline in owner-attributable profit. A widening gap between operating profit and net profit could increase earnings volatility. Tracking debt levels alongside financing costs is necessary.

11

What to watch next

  1. November 27, 2026

    Shareholder vote on the proposed corporate name change. This shows whether the company's identity is being aligned with its health and beauty focus.

  2. Timing not yet set

    Country-by-country approvals and launches under the Latin American licensing and supply agreements with FAES FARMA and a regional partner. This indicates whether prescription drug overseas sales can expand.

  3. End of March 2027 (statutory filing deadline for the annual report)

    The 2026 annual report will show whether annual revenue passes KRW 1 trillion and whether the operating margin holds near the 10.4% of 2025. The fourth-quarter operating profit trend is also part of this check.

  4. Mid-May 2027 (statutory filing deadline for the Q1 quarterly report)

    The Q1 2027 results will show whether the two-quarter operating profit decline ends and whether overseas sales continue the rise from KRW 32.7 billion in the first quarter of 2026 to KRW 43.8 billion in the third.

12

Overall view

Dong Kook Pharmaceutical's annual revenue and operating profit have recovered since 2023, and cumulative revenue through the third quarter of 2026 reached KRW 768.6 billion, up 12.4% year on year.

Growth is centered on overseas health and beauty and prescription drugs, with overseas sales at KRW 117 billion through September 2026. However, third-quarter operating profit of KRW 23.8 billion fell year on year, and owner-attributable profit dropped 33.0%, extending a two-quarter slowdown in earnings.

Higher selling costs, rising financing costs and weakness at subsidiary DongKook Life Science are the main negatives on profit. On the positive side are the market share of long-established OTC brands, cumulative sales of the Madecassol cream and rapid growth in health and beauty.

Annual revenue of KRW 1 trillion sits within reach if about KRW 231.4 billion more is booked in the fourth quarter, but the company has not published an annual revenue forecast. The next step is to check the annual operating margin and whether fourth-quarter profit recovers in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. kr.investing.com
  2. e-focus.co.kr
  3. medicaldaily.co.kr
  4. dailian.co.kr
  5. ajunews.com
  6. supple.kr
  7. newspim.com
  8. insight.co.kr
  9. pinpointnews.co.kr
  10. the-pr.co.kr
  11. medipana.com
  12. dealsite.co.kr
  13. segyenews.com
  14. apsk.co.kr
  15. m.sedaily.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis